Higher mortality risk with digoxin treatment, particularly in those with atrial fibrillationVamos et al., Eur Heart J. 2015
Digoxin-associated mortality: a systematic review and meta-analysis of the literature
Vamos M, Erath JW, Hohnloser SH.
Eur Heart J. May 4 2015. DOI: http://dx.doi.org/10.1093/eurheartj/ehv143
BackgroundDigoxin has been used in clinical practice for over 200 years, mainly as treatment of symptomatic heart failure (HF) in patients with impaired left-ventricular function and of rate control in patients with atrial fibrillation (AF). Although evidence supporting its use for these indications is limited, the indications are endorsed by recent guideline recommendations [1-3].
Digoxin has a narrow therapeutic window, partly related to significant drug-drug interactions. Careful administration encompassing regular measurement of serum digoxin levels is needed to prevent harm. The benefit of digoxin in addition to contemporary HF treatment has recently been challenged [4-9], and some observations even suggest a possible negative effect on mortality.
Considering the conflicting data, a systematic review of published data was performed to estimate the safety of digoxin therapy in the patient populations. Data from 19 studies of original databases were included in the analysis, comprising data from 235047 AF patients and 91379 patients with HF, with follow-up time ranging from 0.83 to 4.7 years (average: 2.57+1.13 years). Only one randomised controlled clinical trial could be included, the rest of the studies were retrospective or prospective observational studies.
- In the analysis of all 19 trials, digoxin use was associated with a 21% higher relative risk of all-cause mortality as compared to patients not receiving digoxin (HR: 1.21, 95%CI: 1.07-1.38, P<0.01).
- In AF patients, digoxin was associated with a 29% higher mortality risk as compared to AF patients who did not receive digoxin (HR: 1.29, 95%CI: 1.21-1.39, P<0.01).
- HF patients receiving digoxin also showed a higher mortality risk than HF patients not on digoxin (HR: 1.14, 95%CI: 1.06-1.22, P<0.01).
- Three large studies reported all-cause mortality data for subgroups of patients with AF and HF. Pooling these studies showed a statistically significantly increased digoxin-related mortality risk for AF patients (HR: 1.28, 95%CI; 1.12-1.46, P<0.01), but not for patients with congestive HF (HR: 1.05, 95%CI: 0.91-1.20, P=0.52).
ConclusionThis meta-analysis on the effects of digoxin on all-cause mortality indicates that digoxin is associated with increased mortality risk in patients with AF or congestive HF. The effect was strongest in AF patients. These observations call for randomised trials evaluating dose-adjusted digoxin therapy. Until those have been completed, digoxin should be used with great caution, especially when used for rate control in AF.
Find this article online at Eur Heart J
1. McMurray JJ, Adamopoulos S, Anker SD, et al. Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, et al., ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology.
Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803–869.
2. Camm AJ, Lip GY, De Caterina R, et al, ESC Committee for Practice Guidelines-CPG; Document Reviewers. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385–1413.
3. Yancy CW, Jessup M, Bozkurt B, et al. ,American College of Cardiology Foundation;American Heart Association Task Force on Practice Guidelines. 2013ACCF/AHAguideline for the management of heart failure: a report of theAmerican College of Cardiology Foundation/American Heart Association Task Force on Practice
Guidelines. J Am Coll Cardiol 2013;62:e147–e239.
4. Hallberg P, Lindba¨ck J, Lindahl B, et al, RIKS-HIAgroup. Digoxin and mortality in atrial fibrillation: a prospective cohort study. Eur J Clin Pharmacol 2007;63:959–971.
5. Friberg L, Hammar N, Rosenqvist M. Digoxin in atrial fibrillation: report from the Stockholm Cohort study of Atrial Fibrillation (SCAF). Heart 2010;96:275–280.
6. Fauchier L, Grimard C, Pierre B, et al. Comparison of beta blocker and digoxin alone and in combination for management of patients with atrial fibrillation and heart failure.Am J Cardiol 2009; 103:248–254.
7. Dhaliwal AS, Bredikis A, Habib G, et al. Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy. Am J Cardiol 2008;102:1356–1360.
8. Butler J, Anand IS, Kuskowski MA, et al. Val-HeFT Investigators. Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT). Congest Heart Fail 2010;16:191–195.
9. Freeman JV, Yang J, Sung SH, et al. Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure. Circ Cardiovasc Qual Outcomes 2013;6:525–533.